Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

180.43 -5.00 (-2.70%)

Streaming Delayed Price Updated: 2:27 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗

March 05, 2025

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

Via Talk Markets

Topics Stocks / Equities

A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts ↗

March 05, 2025

Via Benzinga

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline ↗

March 05, 2025

Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.

Via Benzinga

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 05, 2025

From Chimerix, Inc.; Jazz Pharmaceuticals plc

Via GlobeNewswire

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗

February 13, 2025

Via Benzinga

NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗

November 04, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying.

Via Chartmill

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗

March 05, 2025

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Via Investor's Business Daily

3 Small-Cap Stocks Skating on Thin Ice

March 04, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 26, 2025

Via Benzinga

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Viatris Earnings: What To Look For From VTRS

February 26, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Via StockStory

In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals ↗

October 23, 2024

Via Benzinga

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales

February 25, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect

February 24, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying. ↗

February 19, 2025

JAZZ PHARMACEUTICALS PLC may be an undervalued stock option. NASDAQ:JAZZ retains a strong financial foundation and an attractive price tag.

Via Chartmill

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents. ↗

January 29, 2025

When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗

January 08, 2025

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.

Via Chartmill

NASDAQ:JAZZ is an undervalued gem with solid fundamentals. ↗

December 17, 2024

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.

Via Chartmill

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements ↗

December 09, 2024

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and...

Via Benzinga

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗

November 27, 2024

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

Via Benzinga

NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

November 25, 2024

For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.

Via Chartmill

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework ↗

November 21, 2024

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

Via Benzinga

UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy ↗

November 08, 2024

Via Benzinga

Topics Cannabis

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? ↗

November 06, 2024

CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.

Via Benzinga

Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker ↗

October 18, 2024

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!

Via The Motley Fool

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗

October 15, 2024

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...

Via Benzinga

NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

October 14, 2024

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.